Plasma exposure of free linezolid and its ratio to minimum inhibitory concentration varies in critically ill patients

International Journal of Antimicrobial Agents

Volumn 42, Issue 4, 2013, Pages 329-334

  Yagi, Tatsuya ^a   Naito, Takafumi ^a   Doi, Matsuyuki ^a   Nagura, Osanori ^a   Yamada, Takahiro ^a   Maekawa, Masato ^a   Sato, Shigehito ^a   Kawakami, Junichi ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Critically ill; Linezolid; MRSA; Percentage bound; Pharmacokinetic; Tissue distribution

Indexed keywords

CREATININE; LINEZOLID; SPARFLOXACIN;

ABDOMINAL INFECTION; ADULT; AGED; ARTICLE; BLOOD SAMPLING; BLOODSTREAM INFECTION; CHEST INFECTION; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DISEASE ASSOCIATION; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; FREE AREA UNDER THE CONCENTRATION TIME CURVE MINIMUM INHIBITORY CONCENTRATION RATIO; HUMAN; HYPOALBUMINEMIA; KIDNEY DYSFUNCTION; LUNG INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; PHARMACOLOGICAL PARAMETERS; PLASMA; PRIORITY JOURNAL; SURGICAL INFECTION; TISSUE DISTRIBUTION; TOTAL AREA UNDER THE CONCENTRATION TIME CURVE MINIMUM INHIBITORY CONCENTRATION RATIO; UNSPECIFIED SIDE EFFECT;

CRITICALLY ILL; LINEZOLID; MRSA; PERCENTAGE BOUND; PHARMACOKINETIC; TISSUE DISTRIBUTION;

ACETAMIDES; ADMINISTRATION, INTRAVENOUS; AGED; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; CRITICAL ILLNESS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OXAZOLIDINONES; PLASMA; STAPHYLOCOCCAL INFECTIONS;

EID: 84884700559     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2013.06.015     Document Type: Article

References (26)

1. E. Rubinstein, R. Isturiz, H.C. Standiford, L.G. Smith, T.H. Oliphant, and S. Cammarata Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies Antimicrob Agents Chemother 47 2003 1824 1831
2. M.S. Dryden Linezolid pharmacokinetics and pharmacodynamics in clinical treatment J Antimicrob Chemother 66 Suppl. 4 2011 iv7 iv15
3. A.M. Lovering, J. Zhang, G.C. Bannister, B.J. Lankester, J.H. Brown, and G. Narendra Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement J Antimicrob Chemother 50 2002 73 77
4. B. Rana, I. Butcher, P. Grigoris, C. Murnaghan, R.A. Seaton, and C.M. Tobin Linezolid penetration into osteo-articular tissues J Antimicrob Chemother 50 2002 747 750
5. F. Traunmuller, M.V. Schintler, S. Spendel, M. Popovic, O. Mauric, and E. Scharnagl Linezolid concentrations in infected soft tissue and bone following repetitive doses in diabetic patients with bacterial foot infections Int J Antimicrob Agents 36 2010 84 86
6. T. Gee, R. Ellis, G. Marshall, J. Andrews, J. Ashby, and R. Wise Pharmacokinetics and tissue penetration of linezolid following multiple oral doses Antimicrob Agents Chemother 45 2001 1843 1846
7. D.J. Stalker, and G.L. Jungbluth Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial Clin Pharmacokinet 42 2003 1129 1140
8. K. Attassi, E. Hershberger, R. Alam, and M.J. Zervos Thrombocytopenia associated with linezolid therapy Clin Infect Dis 34 2002 695 698
9. D.C. Vinh, and E. Rubinstein Linezolid: a review of safety and tolerability J Infect 59 Suppl. 1 2009 S59 S74
10. K. Matsumoto, A. Takeshita, K. Ikawa, A. Shigemi, K. Yaji, and Y. Shimodozono Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction Int J Antimicrob Agents 36 2010 179 181
11. F. Pea, M. Furlanut, P. Cojutti, F. Cristini, E. Zamparini, and L. Franceschi Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis Antimicrob Agents Chemother 54 2010 4605 4610
12. M. Ulldemolins, J.A. Roberts, J. Rello, D.L. Paterson, and J. Lipman The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients Clin Pharmacokinet 50 2011 99 110
13. A.P. MacGowan Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections J Antimicrob Chemother 51 Suppl. 2 2003 ii17 ii25
14. M.J. Gentry-Nielsen, K.M. Olsen, and L.C. Preheim Pharmacodynamic activity and efficacy of linezolid in a rat model of pneumococcal pneumonia Antimicrob Agents Chemother 46 2002 1345 1351
15. H. Dong, X. Wang, Y. Dong, J. Lei, H. Li, and H. You Clinical pharmacokinetic/pharmacodynamic profile of linezolid in severely ill intensive care unit patients Int J Antimicrob Agents 38 2011 296 300
16. Clinical and Laboratory Standards Institute Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. Document M7-A7 7th ed. 2006 CLSI Wayne, PA
17. M.E. Brier, D.J. Stalker, G.R. Aronoff, D.H. Batts, K.K. Ryan, and M. O'Grady Pharmacokinetics of linezolid in subjects with renal dysfunction Antimicrob Agents Chemother 47 2003 2775 2780
18. C. Buerger, N. Plock, P. Dehghanyar, C. Joukhadar, and C. Kloft Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis Antimicrob Agents Chemother 50 2006 2455 2463
19. F. Traunmüller, M.V. Schintler, S. Spendel, M. Popovic, O. Mauric, and E. Scharnagl Linezolid concentrations in infected soft tissue and bone following repetitive doses in diabetic patients with bacterial foot infections Int J Antimicrob Agents 36 2010 84 86
20. A. Heinze, and U. Holzgrabe Determination of the extent of protein binding of antibiotics by means of an automated continuous ultrafiltration method Int J Pharm 311 2006 108 112
21. S. Finfer, R. Bellomo, S. McEvoy, S.K. Lo, J. Myburgh, and B. Neal Effect of baseline serum albumin concentration on outcome of resuscitation with albumin or saline in patients in intensive care units: analysis of data from the Saline versus Albumin Fluid Evaluation (SAFE) study BMJ 333 2006 1044
22. R. Beer, K.W. Engelhardt, B. Pfausler, G. Broessner, R. Helbok, and P. Lackner Pharmacokinetics of intravenous linezolid in cerebrospinal fluid and plasma in neurointensive care patients with staphylococcal ventriculitis associated with external ventricular drains Antimicrob Agents Chemother 51 2007 379 382
23. P. Myrianthefs, S.L. Markantonis, K. Vlachos, M. Anagnostaki, E. Boutzouka, and D. Panidis Serum and cerebrospinal fluid concentrations of linezolid in neurosurgical patients Antimicrob Agents Chemother 50 2006 3971 3976
24. Y. Ikeda-Dantsuji, H. Hanaki, F. Sakai, K. Tomono, Y. Takesue, and J. Honda Linezolid-resistant Staphylococcus aureus isolated from 2006 through 2008 at six hospitals in Japan J Infect Chemother 17 2011 45 51
25. P. Wilson, J.A. Andrews, R. Charlesworth, R. Walesby, M. Singer, and D.J. Farrell Linezolid resistance in clinical isolates of Staphylococcus aureus J Antimicrob Chemother 51 2003 186 188
26. L.M. Boak, J. Li, C.R. Rayner, and R.L. Nation Pharmacokinetic/ pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model Antimicrob Agents Chemother 51 2007 1287 1292